Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Trading 05-28 13:24:17 EDT

1.92

-0.01

-0.58%

High1.99	Low1.86	Vol566.47K
Open1.86	D1 Closing1.93	Amplitude6.74%
Mkt Cap284.49M	Tradable Cap276.56M	Total Shares148.26M
T/O1.10M	T/O Rate0.39%	Tradable Shares144.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":1.9189,"timestamp":1716917042220,"preClose":1.93,"halted":0,"volume":566471,"delay":0,"floatShares":144123466,"shares":148255663,"eps":-0.464929,"marketStatus":"Trading","change":-0.0111,"latestTime":"05-28 13:24:17 EDT","open":1.86,"high":1.99,"low":1.86,"amount":1098168.4412527,"amplitude":0.067358,"askPrice":1.92,"askSize":2867,"bidPrice":1.91,"bidSize":1937,"shortable":3,"etf":0,"ttmEps":-0.464929,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716926400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":1.93,"preHourTrading":{"tag":"盘前","latestPrice":1.88,"preClose":1.93,"latestTime":"09:27 EDT","volume":959,"amount":1795.8424840999999,"timestamp":1716902851349},"postHourTrading":{"tag":"盘后","latestPrice":1.9398,"preClose":1.93,"latestTime":"19:57 EDT","volume":4726,"amount":9123.14,"timestamp":1716595069750},"volumeRatio":1.190072,"impliedVol":0.7997,"impliedVolPercentile":0.2191},"requestUrl":"/m/hq/s/XERS/","defaultTab":"news","newsList":[{"id":"2435356228","title":"Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), AMN Healthcare Services (AMN) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435356228","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435356228?lang=en_us&edition=fundamental","pubTime":"2024-05-14 17:00","pubTimestamp":1715677234,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xeris Pharmaceuticals (XERS – Research Report), AM...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xeris-pharmaceuticals-xers-amn-healthcare-services-amn-and-4d-molecular-therapeutics-fdmt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-xeris-pharmaceuticals-xers-amn-healthcare-services-amn-and-4d-molecular-therapeutics-fdmt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434893284","title":"Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2434893284","media":"GuruFocus.com","top":-1,"share":"https://ttm.financial/m/news/2434893284?lang=en_us&edition=fundamental","pubTime":"2024-05-11 03:21","pubTimestamp":1715368895,"startTime":"0","endTime":"0","summary":"Revenue: Reported Q1 2024 revenue of $40.6 million, up 22% year-over-year, falling short of estimates of $41.81 million.Net Loss: Q1 2024 net loss widened to $19.0 million from $16.8 million in Q1 2023, above the estimated net loss of $16.63 million.Earnings Per Share : Reported EPS of -$0.14, below the estimated EPS of -$0.12.Cash Position: Ended Q1 with $87.4 million in cash, cash equivalents, and short-term investments, up from $72.5 million at the end of the previous quarter.Product Sales: Gvoke sales increased by 10% to $16.6 million, Keveyis sales rose by 3% to $13.1 million, and Recorlev sales surged by 137% to $10.6 million.Research and Development: R&D expenses increased by $3.0 million to $7.8 million, reflecting continued investment in pipeline development.On May 9, 2024, Xeris Biopharma Holdings Inc  disclosed its financial results for the first quarter ended March 31, 2024, through an 8-K filing. The company reported a robust increase in total revenue, achieving $40.6 mill","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cexf5PMIayw16b34RdVLmw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/15fc3ba8c98bb4d3ea06cdbaffe63937","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cexf5PMIayw16b34RdVLmw--~B/aD01NTc7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/15fc3ba8c98bb4d3ea06cdbaffe63937"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-xers-192135993.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434856896","title":"Xeris Biopharma Holdings First Quarter 2024 Earnings: Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2434856896","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2434856896?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:23","pubTimestamp":1715343829,"startTime":"0","endTime":"0","summary":"NasdaqGS:XERS Earnings and Revenue Growth May 10th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 2.8%. Earnings per share  also missed analyst estimates by 20%.Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Pharmaceuticals industry in the US.The company's shares are up 1.1% from a week ago.Every company has them, and we've spotted   2 warning signs for Xeris Biopharma Holdings   (of which 1 doesn't sit too well with us!","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-first-quarter-122349877.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434830207","title":"Xeris Pharmaceuticals (XERS) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2434830207","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434830207?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:57","pubTimestamp":1715342267,"startTime":"0","endTime":"0","summary":"In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a pric...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-receives-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/xeris-pharmaceuticals-xers-receives-a-buy-from-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434049189","title":"Xeris Biopharma Holdings Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2434049189","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434049189?lang=en_us&edition=fundamental","pubTime":"2024-05-10 02:43","pubTimestamp":1715280213,"startTime":"0","endTime":"0","summary":"* Xeris Biopharma Holdings Inc    reported a quarterly adjusted loss of 14 cents per share for the quarter ended in January, lower than the same quarter last year, when the company reported EPS of -12","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434097718","title":"Craig-Hallum Reaffirms Their Buy Rating on Xeris Pharmaceuticals (XERS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2434097718","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434097718?lang=en_us&edition=fundamental","pubTime":"2024-05-09 21:16","pubTimestamp":1715260580,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report). The co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-xeris-pharmaceuticals-xers-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-reaffirms-their-buy-rating-on-xeris-pharmaceuticals-xers-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434015330","title":"Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2434015330","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2434015330?lang=en_us&edition=fundamental","pubTime":"2024-05-09 20:10","pubTimestamp":1715256607,"startTime":"0","endTime":"0","summary":"Xeris Biopharma  came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.Xeris Biopharma , which belongs to the Zacks Medical - Drugs industry, posted revenues of $40.64 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.21%. This compares to year-ago revenues of $33.2 million. The company has topped consensus revenue estimates two times over the last four quarters.Xeris Biopharma shares have lost about 21.3% since the beginning of the year versus the S&P 500's gain of 8.8%.While Xeris Biopharma has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - D","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-xers-reports-q1-121007000.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434095036","title":"Xeris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02, revenue of $40.64M misses by $1.17M","url":"https://stock-news.laohu8.com/highlight/detail?id=2434095036","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434095036?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:16","pubTimestamp":1715253361,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals press release  (NASDAQ:XERS): Q1  GAAP EPS of -$0.14  misses by $0.02.\nRevenue of $40.64M (+22.4% Y/Y)  misses by $1.17M.\nCash, cash equivalents, and short-term investments at March 31, 2024 was $87.4 million compared to $72.5 million at December 31, 2023.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4103511-xeris-pharmaceuticals-gaap-eps-of-0_14-misses-0_02-revenue-of-40_64m-misses-1_17m","is_publish_highlight":false,"gpt_icon":0},{"id":"2434098909","title":"Xeris Biopharma Holdings Q1 EPS $(0.14) Misses $(0.12) Estimate, Sales $40.64M Miss $41.81M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2434098909","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2434098909?lang=en_us&edition=fundamental","pubTime":"2024-05-09 19:05","pubTimestamp":1715252754,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 16.67 percent decrease over losses of $(0.12) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38726651/xeris-biopharma-holdings-q1-eps-0-14-misses-0-12-estimate-sales-40-64m-miss-41-81m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2433673324","title":"Xeris Biopharma Holdings Inc    expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2433673324","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433673324?lang=en_us&edition=fundamental","pubTime":"2024-05-08 01:56","pubTimestamp":1715104608,"startTime":"0","endTime":"0","summary":"* Xeris Biopharma Holdings Inc     is expected to show a rise in quarterly revenue when it reports  results on May 9 for the period ending January 1 0001   * The Chicago Illinois-based  company is exp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433421682","title":"BRIEF-Xeris Enters Into An Exclusive Worldwide Collaboration And License Agreement With Beta Bionics","url":"https://stock-news.laohu8.com/highlight/detail?id=2433421682","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433421682?lang=en_us&edition=fundamental","pubTime":"2024-05-06 19:37","pubTimestamp":1714995428,"startTime":"0","endTime":"0","summary":"May 6  - Xeris Biopharma Holdings Inc   :   * XERIS ENTERS INTO AN EXCLUSIVE WORLDWIDE COLLABORATION AND LICENSE AGREEMENT WITH BETA BIONICS   * XERIS BIOPHARMA: POTENTIAL TO GET DEVELOPMENT PAYMENTS, PLUS LOW DOUBLE-DIGIT ROYALTIES BASED ON FUTURE SALES OF XERIS GLUCAGON FOR PUMPS, PUMP SYSTEMSSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424607","title":"Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta Bionics","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424607","media":"ACCESSWIRE","top":-1,"share":"https://ttm.financial/m/news/2433424607?lang=en_us&edition=fundamental","pubTime":"2024-05-06 19:01","pubTimestamp":1714993260,"startTime":"0","endTime":"0","summary":"For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems.CONCORD, MA / ACCESSWIRE / May 6, 2024 / Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol technology for use in Beta Bionics' proprietary bi-hormonal pump and pump systems.Forward-Looking StatementsAny statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc., including the development and pote","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/iiULiosxpahu8kNrvFtTxw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/51a607c01999677ec729ef773432260c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/iiULiosxpahu8kNrvFtTxw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/51a607c01999677ec729ef773432260c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-enters-exclusive-worldwide-collaboration-110100316.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432809069","title":"Pleasing Signs As A Number Of Insiders Buy Xeris Biopharma Holdings Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2432809069","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432809069?lang=en_us&edition=fundamental","pubTime":"2024-05-02 23:24","pubTimestamp":1714663487,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Xeris Biopharma Holdings, Inc. , that sends out a positive message to the company's shareholders.While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.Check out our latest analysis for Xeris Biopharma Holdings. Xeris Biopharma Holdings Insider Transactions Over The Last Year. The Chief Financial Officer Steven Pieper made the biggest insider purchase in the last 12 months. That single transaction was for US$55k worth of shares at a price of US$1.95 each. That means that an insider was happy to buy shares at above the current price of US$1.75. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price inside","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pleasing-signs-number-insiders-buy-152447972.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432867201","title":"Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432867201","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432867201?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:00","pubTimestamp":1714647600,"startTime":"0","endTime":"0","summary":"CHICAGO, May 02, 2024----Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2024 financial results before the open of the U.S. financial markets on Thursday, May 9, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results.After registering, a confirmation email will be sent, including dial-in details and a unique code for entry. The Company recommends registering a minimum of ten minutes prior to the start of the call. Following the conference call, a replay will be available until Thursday, May 23, 2024 at US: 1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 952508. Allison WeySenior Vice Pre","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/EVz2_DRw5H6Cs1LHjCNWrw--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cbfe914b90362929eacca77dd9f9ce02","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/EVz2_DRw5H6Cs1LHjCNWrw--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cbfe914b90362929eacca77dd9f9ce02"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-report-first-quarter-110000089.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428791343","title":"Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2428791343","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428791343?lang=en_us&edition=fundamental","pubTime":"2024-04-17 19:24","pubTimestamp":1713353040,"startTime":"0","endTime":"0","summary":"MediWound  shares soared 14.3% in the last trading session to close at $18.28. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1.7% gain over the past four weeks.Last month, the company announced robust financial results for the full year and fourth quarter ended 2023. This might have been driving the share price rally.This developer of treatments for burns and hard-to-heal wounds is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents a year-over-year change of +9.1%. Revenues are expected to be $4.65 million, up 22.3% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.Xeris Biopharma Holdings, Inc.  : Free Stock Analysis Report. To read this article on Zack","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/c7QYGIeMUDIp3mS1qSXkLA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/78361099d48178155a7388f9575187c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/c7QYGIeMUDIp3mS1qSXkLA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/78361099d48178155a7388f9575187c7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-mediwound-mdwd-14-112400418.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425598785","title":"Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) top owners are retail investors with 51% stake, while 45% is held by institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2425598785","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2425598785?lang=en_us&edition=fundamental","pubTime":"2024-04-05 23:15","pubTimestamp":1712330126,"startTime":"0","endTime":"0","summary":"The considerable ownership by retail investors in Xeris Biopharma Holdings indicates that they collectively have a greater say in management and business strategy. 43% of the business is held by the top 25 shareholders. To get a sense of who is truly in control of Xeris Biopharma Holdings, Inc. , it is important to understand the ownership structure of the business. With 51% stake, retail investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises .Institutions, on the other hand, account for 45% of the company's stockholders. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones.While the precise definition of an insider can be subjective, almost everyone consid","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H9sVDVM9mi9ws1HvXhxW7w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-holdings-inc-nasdaq-151526745.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424018348","title":"Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2424018348","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2424018348?lang=en_us&edition=fundamental","pubTime":"2024-04-02 19:00","pubTimestamp":1712055600,"startTime":"0","endTime":"0","summary":"Xeris  is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, a proven therapy for primary periodic paralysis, and Recorlev for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol and XeriJect, supporting long-term product development and commercial success.Allison WeySenior Vice President, Investor Relations and Corporate Communicationsawey@xerispharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R0e0ES5uTyi.Z5Qie6RteQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffef3fb4d3b44c3357ac89e15d667ba4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R0e0ES5uTyi.Z5Qie6RteQ--~B/aD0yNzQ7dz04MDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ffef3fb4d3b44c3357ac89e15d667ba4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xeris-biopharma-participate-23rd-annual-110000573.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2423182471","title":"Xeris Biopharma: Checking-In On One Of My 'Top Ideas'","url":"https://stock-news.laohu8.com/highlight/detail?id=2423182471","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2423182471?lang=en_us&edition=fundamental","pubTime":"2024-03-30 13:28","pubTimestamp":1711776533,"startTime":"0","endTime":"0","summary":"Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a \"Top Idea\" in the Compounding Healthcare Investing Group.Xeris has three approved products and a strong pipeline, with p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4681270-xeris-biopharma-checking-in-on-one-of-my-top-ideas","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":-0.0253},{"period":"1month","weight":0.0966},{"period":"3month","weight":-0.3588},{"period":"6month","weight":0},{"period":"1year","weight":-0.3204},{"period":"ytd","weight":-0.1787}],"compareEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.0425},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.2768},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.091365},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.026041},{"month":3,"riseRate":0.5,"avgChangeRate":-0.107706},{"month":4,"riseRate":0.5,"avgChangeRate":0.063543},{"month":5,"riseRate":0.666667,"avgChangeRate":0.155859},{"month":6,"riseRate":0.6,"avgChangeRate":-0.082978},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.045103},{"month":8,"riseRate":0.5,"avgChangeRate":0.165434},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.094375},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.059108},{"month":11,"riseRate":0.5,"avgChangeRate":0.006729},{"month":12,"riseRate":0.5,"avgChangeRate":0.047808}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction